SMTIHIGH SIGNALFINANCIAL10-K

SMTI shows severe financial deterioration with net losses widening to $37.6M despite positive operating income, driven by massive debt increases and collapsing stockholder equity.

The company faces a critical financial situation with stockholders' equity plummeting 85% to just $5.9M while total debt surged 50% to $46M, creating significant leverage concerns. The dramatic increase in interest expense to $6.8M is overwhelming the business despite achieving positive operating income, indicating potential debt servicing challenges ahead.

Comparing 2026-03-24 vs 2025-03-25View on EDGAR →
FINANCIAL ANALYSIS

SMTI experienced explosive growth in accounts receivable (up 8,400%) and strong operating cash flow improvement to $6.8M, suggesting significant business expansion or acquisition activity. However, the company's financial foundation deteriorated severely with stockholders' equity collapsing 85% while debt increased 50% to $46M, causing interest expenses to more than double and driving net losses to $37.6M despite positive operating performance. The combination of massive debt growth, equity destruction, and widening net losses despite operational improvements signals a company in financial distress, potentially from aggressive expansion or acquisition financing.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+28634.4%
-$24K$6.8M

Operating cash flow surged 28634.4% — exceptional cash generation, highest quality earnings signal.

Accounts Receivable
Balance Sheet
+8429.9%
$80K$6.8M

Receivables surged 8429.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Capital Expenditure
Cash Flow
+2147.1%
$206K$4.6M

Capital expenditure jumped 2147.1% — major investment cycle underway; assess returns on deployment.

Net Income
P&L
-288.7%
-$9.7M-$37.6M

Net income declined 288.7% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
+208.8%
-$6.7M$7.3M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Interest Expense
P&L
+116.1%
$3.1M$6.8M

Interest expense surged 116.1% — significant debt increase or rising rates materially impacting earnings.

Stockholders Equity
Balance Sheet
-84.9%
$39.4M$5.9M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Debt
Balance Sheet
+49.8%
$30.7M$46.0M

Debt increased 49.8% — substantial leverage increase; assess whether deployed for growth or covering losses.

Inventory
Balance Sheet
+43.4%
$2.8M$3.9M

Inventory surged 43.4% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Total Liabilities
Balance Sheet
+36.3%
$49.2M$67.0M

Liabilities grew 36.3% — significant increase in debt or obligations, assess impact on financial flexibility.

LANGUAGE CHANGES
NEW — 2026-03-24
PRIOR — 2025-03-25
ADDED
As of March 20, 2026, 9,167,040 shares of the registrant s common stock, $ 0.001 par value per share, were issued and outstanding.
MARKET FOR REGISTRANT S COMMON EQUITY, RELATED SHAREHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES 39 ITEM 6.
MANAGEMENT S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 39 ITEM 7A.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 53 ITEM 9A.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 54 ITEM 13.
+7 more — sign up free →
REMOVED
As of March 18, 2025, 8,901,903 shares of the Issuer s common stock, $ 0.001 par value per share, were issued and outstanding.
Forward-looking statements generally relate to future events or our future financial or operating performance, including topics such as our value-based wound and skincare services and Tissue Health Plus platforms.
BUSINESS Overview We are a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets.
Our products, services and technologies are designed to achieve our goal of providing better clinical outcomes at a lower overall cost for patients regardless of where they receive care.
Through our two operating segments, Sanara Surgical and Tissue Health Plus ( THP ), we strive to be one of the most innovative and comprehensive providers of effective surgical, wound and skincare solutions and are continually seeking to expand our offerings for patients requiring treatments across the entire continuum of care in the United States.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →